Guopan Tongji Li

Dr. Guopan Tongji Li

Tongji University, Shanghai, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2024 in Advanced Science
Verified
Journal Article
Open access
GLGuopan Tongji Li
Guopan Tongji Li
HLHengli Lu
Hengli Lu
LFLimin Fan
Limin Fan
XMXiaoyi Ma
Xiaoyi Ma
ZDZhengwei Duan
Zhengwei Duan
YYYunfeng Yang
Yunfeng Yang
Osteoarthritis (OA) is marked by cartilage deterioration, subchondral bone changes, and an inflammatory microenvironment. The study introduces the Microneedle‐Delivered Polydopamine‐Exosome (PDA@Exo MN), a therapeutic that not only preserves cartilage and promotes bone regeneration but also improves localized drug delivery through enhanced penetration capabilities. PDA@Exo MN shows strong reactive oxygen species (ROS) scavenging abilities and high biocompatibility, fostering osteogenesis and balancing anabolic and catabolic processes in cartilage. It directs macrophage polarization from M0 to the anti‐inflammatory M2 phenotype. RNA sequencing of treated chondrocytes demonstrates restored cellular function and activated antioxidant responses, with modulated inflammatory pathways. The PI3K‐AKT‐mTOR pathway's activation, essential for PDA@Exo's effects, is confirmed via bioinformatics and Western blot. In vivo assessments robustly validate that PDA@Exo MN prevents cartilage degradation and OA progression, supported by histological assessments and micro‐CT analysis, highlighting its disease‐modifying impact. The excellent biocompatibility of PDA@Exo MN, verified through histological (H&E) and blood tests showing no organ damage, underscores its safety and efficacy for OA therapy, making it a novel and multifunctional nanomedical approach in orthopedics, characterized by organ‐friendliness and biosecurity.

28 July 2024 in Cancer Science
Verified
Journal Article
Open access
GLGuopan Tongji Li
Guopan Tongji Li
HLHengli Lu
Hengli Lu
YZYiwei Zhang
Yiwei Zhang
JLJiyang Lv
Jiyang Lv
YZYi Zhang
Yi Zhang
YLYuxin Liao
Yuxin Liao
Osteosarcoma, recognized for its aggressiveness and resistance to chemotherapy, notably doxorubicin, poses significant treatment challenges. This comprehensive study investigated the CXCR4–CARM1–YAP signaling axis and its pivotal function in controlling aerobic glycolysis, which plays a crucial role in doxorubicin resistance. Detailed analysis of Dox‐resistant 143b/MG63‐DoxR cells has uncovered the overexpression of CXCR4. Utilizing a combination of molecular biology techniques including gene silencing, aerobic glycolysis assays such as Seahorse experiments, RNA sequencing, and immunofluorescence staining. The study provides insight into the mechanistic pathways involved. Results demonstrated that disrupting CXCR4 expression sensitizes cells to doxorubicin‐induced apoptosis and alters glycolytic activity. Further RNA sequencing revealed that CARM1 modulated this effect through its influence on glycolysis, with immunofluorescence of clinical samples confirming the overexpression of CXCR4 and CARM1 in drug‐resistant tumors. Chromatin immunoprecipitation studies further highlighted the role of CARM1, showing it to be regulated by methylation at the H3R17 site, which in turn affected YAP expression. Crucially, in vivo experiments illustrated that CARM1 overexpression could counteract the tumor growth suppression that resulted from CXCR4 inhibition. These insights revealed the intricate mechanisms at play in osteosarcoma resistance to doxorubicin and pointed toward potential new therapeutic strategies that could target this metabolic and signaling network to overcome drug resistance and improve patient outcomes.

16 December 2022 in Cells
Verified
Journal Article
Open access
PDF file
GLGuopan Tongji Li
Guopan Tongji Li
ZDZhengwei Duan
Zhengwei Duan
KJKeyao Jia
Keyao Jia
YYYiwen Yao
Yiwen Yao
KLKaiyuan Liu
Kaiyuan Liu
Anquan ShangAnquan Shang
Anquan Shang
A study by Tsvetkov et al. recently published a proposed novel form of copper-induced cell death in Science; however, few studies have looked into the possible mechanism in soft tissue sarcoma (STS). Herein, this study sought to investigate the function of cuproptosis-related genes (CRGs) in the development of tumor-associated immune cells and the prognosis of sarcoma. Herein, this study aimed to explore the role of cuproptosis-related genes (CRGs) in the development, tumor-associated immune cells, and the prognosis of sarcoma. Methods: The prognostic model was established via the least absolute shrinkage and selection operator (LASSO) algorithm as well as multivariate Cox regression analysis. The stromal scores, immune scores, ESTIMA scores, and tumor purity of sarcoma patients were evaluated by the ESTIMATE algorithm. Functional analyses were performed to investigate the underlying mechanisms of immune cell infiltration and the prognosis of CRGs in sarcoma. Results: Two molecular subgroups with different CRG expression patterns were recognized, which showed that patients with a higher immune score and more active immune status were prone to have better prognostic survival. Moreover, GO and KEGG analyses showed that these differentially expressed CRGs were mainly enriched in metabolic/ions-related signaling pathways, indicating that CRGs may have impacts on the immune cell infiltration and prognosis of sarcoma via regulating the bioprocess of mitochondria and consequently affecting the immune microenvironment. The expression levels of CRGs were closely correlated to the immunity condition and prognostic survival of sarcoma patients. Conclusions: The interaction between cuproptosis and immunity in sarcoma may provide a novel insight into the study of molecular mechanisms and candidate biomarkers for the prognosis, resulting in effective treatments for sarcoma patients.

24 February 2025 in Interdisciplinary Medicine
Verified
Journal Article
Open access
GLGuopan Tongji Li
Guopan Tongji Li
QCQingjing Chen
Qingjing Chen
YZYi Zhang
Yi Zhang
ZYZhanhui Ye
Zhanhui Ye
YSYixian Song
Yixian Song
ASAnquan Shang
Anquan Shang
Osteosarcoma (OS), the most common primary bone tumor in children and young adults, poses significant clinical challenges. In this study, we investigated the role of exosomes—key mediators of intercellular communication—in OS progression and identified potential therapeutic targets. Functional assays in cellular and animal models demonstrated that OS‐derived exosomes markedly enhanced tumor proliferation, migration, and invasion. Data‐independent acquisition‐based mass spectrometry analysis revealed a notable enrichment of the proto‐oncogene tyrosine‐protein kinase YES1 in these exosomes. Bioinformatics and clinical investigations further showed that YES1 is overexpressed in multiple cancers and correlates with poor outcomes; specifically, in OS, elevated YES1 levels were associated with reduced overall survival and adverse prognoses. PCR, Western blotting, and immunohistochemistry (IHC) of clinical samples confirmed its high expression in OS tissues relative to normal counterparts. Mechanistic studies using YES1 knockdown (shYES1) and overexpression (OE YES1) models, coupled with exosome supplementation and pathway modulators, revealed a critical role for ERK phosphorylation in mediating YES1‐driven oncogenic behaviors. In shYES1 cells, tumor proliferation, migration, and invasion were significantly impaired, partially rescued by exosome supplementation, and further suppressed by the inhibitor of MAPK. Conversely, in OE YES1 cells, these malignant phenotypes were markedly enhanced, exacerbated by exosomes, and further promoted by the agonist of MAPK. Western blot analyses supported these observations, showing reduced p‐MEK and p‐ERK but increased p‐p38 and p‐JNK upon YES1 knockdown, with opposite trends in the OE YES1 group; these phosphorylation changes were reversed or attenuated by EGF/IL‐1beta or U0126/SB‐203580 treatment, respectively, without altering total protein levels of MEK, JNK, p38, and ERK. Finally, multiplex IHC validated bioinformatics predictions, demonstrating that YES1 expression is closely linked to immune‐related pathways in OS tissues. Collectively, these findings underscore the pivotal role of exosomal YES1 in OS progression and tumor immunology, highlighting its promise as a biomarker and therapeutic target. By illuminating its function in cancer behavior and immune interactions, this study offers novel insights into improving patient outcomes in OS.

15 January 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
PZPengfei Zan
Pengfei Zan
YZYi Zhang
Yi Zhang
YZYidong Zhu
Yidong Zhu
QCQingjing Chen
Qingjing Chen
ZDZhengwei Duan
Zhengwei Duan
GLGuopan Tongji Li
Guopan Tongji Li
Sarcoma (SARC), a diverse group of stromal tumors arising from mesenchymal tissues, is often associated with a poor prognosis. Emerging evidence indicates that senescent cells within the tumor microenvironment (TME) significantly contribute to cancer progression and metastasis. Although the influence of senescence on SARC has been partially acknowledged, it has yet to be fully elucidated. In this study, we revealed that senescence level and age were associated with TME, immune treatment indicators, and prognosis in SARC. Utilizing the weighted gene co-expression network analysis and least absolute shrinkage and selection operator algorithm, we identified senescence-related genes and developed a senescence predictor. Three genes, RAD54, PIK3IP1, and TRIP13, were selected to construct a multiple linear regression model. Validation cohorts, immunohistochemistry, and quantitative reverse transcription polymerase chain reaction confirmed that the predictor derived from these three genes possessed prognostic and pathological relevance. Our senescence predictor provides comprehensive insights into the molecular mechanisms of SARC and identifies potential biomarkers for prognosis, paving the way for effective treatments. The results of this study hold promise for developing therapeutic strategies tailored to the unique characteristics of SARC.